ReviewJournal of pharmaceutical policy and practice2024
A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries.
Review in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Effectiveness of vitamin E in the treatment of diabetic neuropathy: systematic review and meta-analysis.Hormones (Athens, Greece) · 2026Pooled it
- Effects of Dietary Fruit and Vegetable Consumption on Prediabetes: A Systematic Review and Meta-Analysis.Nutrients · 2026Pooled it
- SGLT2 versus DPP-4 inhibitors in type 2 diabetes: a meta-analysis of outcomes.Frontiers in endocrinology · 2026Pooled it
- Observational
- Exploring the Socio-Economic Toll of Non-Communicable Diseases in Low-Resource Settings: Novel Evidence From Mozambique.The International journal of health planning and management · 2026Article
- Trends in self-reported current diabetes care use, socioeconomic inequalities, and associated factors in Japan: evidence from the Comprehensive Survey of Living Conditions (1986-2022).BMJ open diabetes research & care · 2026Article
- Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model.Diabetes, obesity & metabolism · 2026Article
- Development, structure, and implementation of cardiometabolic clinics in the United States, with a focus on comprehensive patient care.American journal of preventive cardiology · 2026Review
- Article
- Patient Perspectives on Quantified Self Technologies and Healthcare Costs Among Patients with Diabetes in Zimbabwe.International journal of environmental research and public health · 2026Article
- Optimising care for uncomplicated type 2 diabetes mellitus in Lagos, Nigeria: cost and benefit estimates using real-world data.BMJ global health · 2026Article
- Exploring insulin rejection through photo-elicitation among informal caregivers and patients with type 2 diabetes mellitus.Korean journal of family medicine · 2026Article
- The effect of community-based health insurance on out-of-pocket expenditure among diabetic patients at hawassa university comprehensive specialized hospital: facility-based comparative cross-sectional study.BMC health services research · 2026Article
- Economic Burden of Type 2 Diabetes Mellitus Among Patients Attending Ho Teaching Hospital in the Ho Municipality, Ghana: A Cross-Sectional Study.Health science reports · 2026Article
- Risk assessment for type 2 diabetes mellitus and its association with knowledge and health beliefs among university students in three Arab countries.Scientific reports · 2026Article
- Body mass index impact on health care utilization among people with diabetes in Jeddah, Saudi Arabia.Frontiers in public health · 2026Article
- Confronting the economic burden of diabetes: Can TCM DRG payment reform in China offer a viable solution? Insights from empirical research in Western China.Frontiers in public health · 2026Article
- Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol.Journal of pharmaceutical policy and practice · 2026Article
- Associations Between Body Mass Index Trajectories and Healthcare Utilization and Costs Among Patients with Type 2 Diabetes in Finland.Clinical epidemiology · 2026Article
- Economic impact of education and empowerment interventions in diabetes care: a two-year prospective longitudinal analysis in a tertiary care population.Frontiers in clinical diabetes and healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diabetes increases preventative sickness and costs healthcare and productivity. Type 2 diabetes and macrovascular disease consequences cause most diabetes-related costs. Type 2 diabetes greatly costs healthcare institutions, reducing economic productivity and efficiency. This cost of illness (COI) analysis examines the direct and indirect costs of treating and managing type 1 and type 2 diabetes mellitus. Methodology: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Cochrane, PubMed, Embase, CINAHL, Scopus, Medline Plus, and CENTRAL were searched for relevant articles on type 1 and type 2 diabetes illness costs. The inquiry returned 873 2011-2023 academic articles. The study included 42 papers after an abstract evaluation of 547 papers. Results: Most articles originated in Asia and Europe, primarily on type 2 diabetes. The annual cost per patient ranged from USD87 to USD9,581. Prevalence-based cost estimates ranged from less than USD470 to more than USD3475, whereas annual pharmaceutical prices ranged from USD40 to more than USD450, with insulin exhibiting the greatest disparity. Care for complications was generally costly, although costs varied significantly by country and problem type. Discussion: This study revealed substantial heterogeneity in diabetes treatment costs; some could be reduced by improving data collection, analysis, and reporting procedures. Diabetes is an expensive disease to treat in low- and middle-income countries, and attaining Universal Health Coverage should be a priority for the global health community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.